149 related articles for article (PubMed ID: 28775207)
1. Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells.
Pickup MW; Owens P; Gorska AE; Chytil A; Ye F; Shi C; Weaver VM; Kalluri R; Moses HL; Novitskiy SV
Cancer Immunol Res; 2017 Sep; 5(9):718-729. PubMed ID: 28775207
[TBL] [Abstract][Full Text] [Related]
2. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
3. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
Saung MT; Muth S; Ding D; Thomas DL; Blair AB; Tsujikawa T; Coussens L; Jaffee EM; Zheng L
J Immunother Cancer; 2018 Nov; 6(1):118. PubMed ID: 30424804
[TBL] [Abstract][Full Text] [Related]
4. Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting.
Cheung PF; Neff F; Neander C; Bazarna A; Savvatakis K; Liffers ST; Althoff K; Lee CL; Moding EJ; Kirsch DG; Saur D; Bazhin AV; Trajkovic-Arsic M; Heikenwalder MF; Siveke JT
Cancer Res; 2018 Sep; 78(17):4997-5010. PubMed ID: 29844119
[TBL] [Abstract][Full Text] [Related]
5. c-Jun N-terminal kinase in pancreatic tumor stroma augments tumor development in mice.
Sato T; Shibata W; Hikiba Y; Kaneta Y; Suzuki N; Ihara S; Ishii Y; Sue S; Kameta E; Sugimori M; Yamada H; Kaneko H; Sasaki T; Ishii T; Tamura T; Kondo M; Maeda S
Cancer Sci; 2017 Nov; 108(11):2156-2165. PubMed ID: 28837246
[TBL] [Abstract][Full Text] [Related]
6. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
Zhang S; Chung WC; Xu K
Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
[TBL] [Abstract][Full Text] [Related]
7. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.
Murakami S; Shahbazian D; Surana R; Zhang W; Chen H; Graham GT; White SM; Weiner LM; Yi C
Oncogene; 2017 Mar; 36(9):1232-1244. PubMed ID: 27546622
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes.
Keklikoglou I; Hosaka K; Bender C; Bott A; Koerner C; Mitra D; Will R; Woerner A; Muenstermann E; Wilhelm H; Cao Y; Wiemann S
Oncogene; 2015 Sep; 34(37):4867-78. PubMed ID: 25500542
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.
Ijichi H; Chytil A; Gorska AE; Aakre ME; Bierie B; Tada M; Mohri D; Miyabayashi K; Asaoka Y; Maeda S; Ikenoue T; Tateishi K; Wright CV; Koike K; Omata M; Moses HL
J Clin Invest; 2011 Oct; 121(10):4106-17. PubMed ID: 21926469
[TBL] [Abstract][Full Text] [Related]
10. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
11. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
12. Aberrant NFATc1 signaling counteracts TGFβ-mediated growth arrest and apoptosis induction in pancreatic cancer progression.
Hasselluhn MC; Schmidt GE; Ellenrieder V; Johnsen SA; Hessmann E
Cell Death Dis; 2019 Jun; 10(6):446. PubMed ID: 31171768
[TBL] [Abstract][Full Text] [Related]
13. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
14. TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer.
Principe DR; Park A; Dorman MJ; Kumar S; Viswakarma N; Rubin J; Torres C; McKinney R; Munshi HG; Grippo PJ; Rana A
Mol Cancer Ther; 2019 Mar; 18(3):613-620. PubMed ID: 30587556
[TBL] [Abstract][Full Text] [Related]
15. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
16. Augmented TGFβ receptor signaling induces apoptosis of pancreatic carcinoma cells.
Li C; Zhao Z; Zhou Z; Liu R
Tumour Biol; 2015 Apr; 36(4):2815-9. PubMed ID: 25476855
[TBL] [Abstract][Full Text] [Related]
17. Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC).
Li Z; Lin P; Gao C; Peng C; Liu S; Gao H; Wang B; Wang J; Niu J; Niu W
Tumour Biol; 2016 Apr; 37(4):5117-31. PubMed ID: 26547582
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
Takeuchi S; Baghdadi M; Tsuchikawa T; Wada H; Nakamura T; Abe H; Nakanishi S; Usui Y; Higuchi K; Takahashi M; Inoko K; Sato S; Takano H; Shichinohe T; Seino K; Hirano S
Cancer Res; 2015 Jul; 75(13):2629-40. PubMed ID: 25952647
[TBL] [Abstract][Full Text] [Related]
19. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
[TBL] [Abstract][Full Text] [Related]
20. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer.
Thomas D; Sagar S; Liu X; Lee HR; Grunkemeyer JA; Grandgenett PM; Caffrey T; O'Connell KA; Swanson B; Marcos-Silva L; Steentoft C; Wandall HH; Maurer HC; Peng XL; Yeh JJ; Qiu F; Yu F; Madiyalakan R; Olive KP; Mandel U; Clausen H; Hollingsworth MA; Radhakrishnan P
Mol Ther; 2021 Apr; 29(4):1557-1571. PubMed ID: 33359791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
